HomeNewsBusinessIPOGo First to delay IPO plans again till November on weak consumer sentiment

Go First to delay IPO plans again till November on weak consumer sentiment

The company says it has been advised to wait for the new ATF pricing mechanism to kick in before firming up IPO plans. The new mechanism is expected to help airlines predict ATF price movements based on international prices and help them be better prepared in case global crude prices rise.

September 09, 2022 / 17:48 IST
Story continues below Advertisement

Wadia group-owned Go First has once again deferred its initial public offering (IPO) to raise Rs 3,600 crore till November on weak consumer sentiment surrounding aviation stocks.

"Go First has been advised to wait for the new ATF pricing mechanism to kick in before launching its IPO. The new ATF pricing mechanism is expected to boost sentiment in the aviation sector," a person aware of the airline’s plans said.

Story continues below Advertisement

ALSO READ: Price war in the sky: Airfares tumble after government lifts fare caps

The airline had planned to come out with its delayed IPO in the second quarter of this financial year, but will now wait for a couple of months before considering a launch.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show